A股異動 | 東寶生物(300239.SZ)逼近跌停 收深交所關注函
格隆匯9月10日丨此前連續2個交易日漲停的東寶生物(300239.SZ)今日高開逾2%後,股價快速走低,盤中一度跌停,現報7.73元,跌19.65%,暫成交8.6億元,最新總市值40億元。東寶生物今日午間宣佈,深交所發行上市審核機構對公司向特定對象發行股票的申請文件進行了審核,認為公司符合發行條件、上市條件和信息披露要求,後續深交所將按規定報中國證監會履行相關注冊程序。此外,東寶生物昨日晚間收到深交所關注函,要求公司核實股價短期內漲幅較大的原因,並説明是否存在對公司股票交易價格可能產生較大影響的未公開重大信息、市場傳聞、熱點概念等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.